Payment overview · 2025
General Payments
$296.30
19 reported records · 8 companies
Healthcare provider profile · identity verified
Darrell T Herrington, DO
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANGELO, TX · NPI 1154388767
Verified facts
What the public records show
CMS Open Payments records show Darrell T Herrington, DO received $296.30 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.28 | 54.1% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.58 | 13.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.61 | 6.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.96 | 6.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.66 | 5.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.87 | 5.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.60 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.74 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.30 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.01 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.01 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $70.27 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 177 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 748 | 204 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 509 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 506 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 134 |
| Losartan Potassium | Losartan Potassium | 395 | 112 |
| Gabapentin | Gabapentin | 371 | 91 |
| Tramadol Hcl | Tramadol Hcl | 360 | 69 |
| Torsemide | Torsemide | 337 | 99 |
| Omeprazole | Omeprazole | 333 | 103 |
| Liothyronine Sodium | Liothyronine Sodium | 300 | 84 |
| Alprazolam | Alprazolam | 294 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 76 |
| Trazodone Hcl | Trazodone Hcl | 224 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 216 | 32 |
| Lisinopril | Lisinopril | 200 | 65 |
| Doxazosin Mesylate | Doxazosin Mesylate | 195 | 54 |
| Metformin Hcl | Metformin Hcl | 193 | 56 |
| Potassium Chloride | Potassium Chloride | 190 | 61 |
| Ozempic | Semaglutide | 177 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 156 | 49 |
| Sertraline Hcl | Sertraline Hcl | 146 | 45 |
| Furosemide | Furosemide | 134 | 43 |
| Methadone Hcl | Methadone Hcl | 132 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 35 |
| Eszopiclone | Eszopiclone | 122 | 21 |
| Pregabalin | Pregabalin | 121 | 20 |
| Febuxostat | Febuxostat | 118 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 115 | 63 |
| Memantine Hcl | Memantine Hcl | 113 | 30 |
| Simvastatin | Simvastatin | 110 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 30 |
| Lorazepam | Lorazepam | 101 | 26 |
| Baclofen | Baclofen | 98 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 91 | 13 |
| Celecoxib | Celecoxib | 87 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 60 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 27 |
| Synthroid | Levothyroxine Sodium | 78 | 25 |
| Carvedilol | Carvedilol | 77 | 24 |
| Clonazepam | Clonazepam | 75 | 12 |
| Levofloxacin | Levofloxacin | 74 | 60 |
| Montelukast Sodium | Montelukast Sodium | 74 | 19 |
| Spironolactone | Spironolactone | 74 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 71 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 16 |
| Ondansetron Odt | Ondansetron | 63 | 18 |
| Eliquis | Apixaban | 60 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 53 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 52 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 52 | suppressed |
| Glipizide | Glipizide | 51 | 19 |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 17 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 18 |
| Estradiol | Estradiol | 42 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 11 |
| Buprenorphine Hcl | Buprenorphine Hcl | 39 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 12 |
| Topiramate | Topiramate | 39 | 14 |
| Prednisone | Prednisone | 38 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 12 |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | 11 |
| Nifedipine Er | Nifedipine | 36 | 11 |
| Verapamil Er | Verapamil Hcl | 36 | 12 |
| Calcitriol | Calcitriol | 35 | 11 |
| Famotidine | Famotidine | 35 | 11 |
| Rybelsus | Semaglutide | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Finasteride | Finasteride | 31 | 11 |
| Temazepam | Temazepam | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | 11 |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | 13 |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 20 |
| Methylphenidate Er | Methylphenidate Hcl | 24 | suppressed |
| Testosterone | Testosterone | 24 | 11 |
| Valsartan | Valsartan | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Dexamethasone | Dexamethasone | 16 | 16 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluorouracil | Fluorouracil | 16 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.30 · 19 records | Novo Nordisk Inc | Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error